Novus Acquisition (NDEV) MedPlan Issues Next Level Strategy

Next Level Strategy Focus On Continual Profitable Growth

Novus Chief Executive Officer, Frank Labrozzi, stated, “As we see mid-term elections upon us, we see the promise legalized cannabis growing until it is approved federally. Since the second quarter of 2016, Novus has generated consistent growth with our disciplined focus and persistent business model execution; we are continuing our drive towards world-class efficiency as an international health insurance entity. The positive results of our disclosure statements are a direct magnitude of our performance over the past 18 months despite being limited in depository relationships in banking and branding initiatives by major Internet networks. However these drawbacks are easing, we see a robust attentiveness to our business model from the cannabis consumer and vendors, impacting Novus’ quarterly results.”

Novus’ sustained growth is and will be attributed to the following four next level strategies that are being deployed:

i.         The alignment of Big Pharma, Retail Pharmacies and Health Plan Carrier as they gather strong holds in medical cannabis sector

ii.         Which will augment the expansion and roll out of Novus MedPlan, globally

iii.         Locking up strategic relationships with Professional Employment Organization’s (PEO) to sell Novus Cannabis MedPlan as employee benefits

(i) Alignment of Big Pharma Retail Pharmacies and Health Insurance

Strongholds in the future cannabis sector will be in the three key areas:

a)     Intellectual Property (IP): Pharmaceuticals Manufacturers market share will be through R&D and/or acquisition of cannabis IP as they identify safe and efficient medical delivery systems. This has already been demonstrated with Pfizer, GW Pharma, Merck & Co, and Sanofi-Aventis being heavily involved in cannabis, controlling IP and the leading cannabis patent holders in Canada.

b)    Distribution: CVS Pharmacies, with approximately 10,000 retail locations nationwide, has filed for 300 cannabis licenses in the State of California alone. The assumption of this move can be either being a suitable distribution on retail side or a secretive alignment with Big Pharma. Either way health insurance/Novus will be a part of the alignment.

c)     Consumerism: Customarily, health insurance carriers play a vital role in establishing a free market in drug pricing as new drugs emerge into the marketplace. Novus is setting its sights on the future where Big Pharma, Pharmacies and Health Insurance will eventually come into a competitive harmony on pricing. This has been done over decades where health carriers can leverage the pricing issue to the amount patient/members it covers, or perhaps causing hurdles and obstacles to a certain brands.

(ii) Global Expansion

As the world applauds Canada as it makes history in cannabis, and the overall global market as countries are approving medicinal cannabis despite geopolitical uncertainties that arose two years ago. Currently there are thirty nations that have some sort of cannabis legalization and Novus’ management has identified fifteen markets to begin its first mover advantage in filing its insurance footprint in:

Germany

United Kingdom

Israel

Australia

Italy

Norway

South America

Romania

Switzerland

Uruguay

Netherlands

Finland

Norway

Poland

Denmark